ClinicalTrials.gg
CompletedNCT01522547SCD-001Updated Nov 8, 2019

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

A Phase 1 interventional study of pomalidomide in Anemia, Sickle Cell, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 5 months after the study started (first participant enrolled Aug 2007, registered Jan 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
430th of 559
12 · median 31
Started
2007
with 14 others
Phase 1
98 of 733
13 open now
Registered
187th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 430th largest by planned enrollment of the 559 interventional ones that give a count, is one of 15 that started in 2007, is one of 98 in phase 1, and was the 187th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the maximum tolerated dose, safety and effect on induction of fetal hemoglobin of pomalidomide in patients with Sickle Cell Disease.

03

Conditions studied

  • Anemia, Sickle Cell

Keywords

  • Pomalidomide
  • Sickle Cell Disease
  • Fetal Hemoglobin
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 to 60 years, inclusive, at the time of signing the form
  • Sickle Cell Disease (SCD) documented as Sickle Cell Anemia or Sickle Beta-Zero Thalassemia
  • Clinically significant SCD defined as at least 1 documented pain episode per year averaged over the past 3 years or one episode of active leg ulcers, priapism, or acute chest syndrome over the past 3 years
  • Failed to achieve at least an absolute 5% increase in F while taking Hydroxyurea (HU) or unable to tolerate HU as described by the treating physician and may include but is not limited to lack of efficacy (such as people who have continued to have pain episodes more than 2 times a year or who have had acute chest or multiorgan failure syndromes or an episode of priapism), or other severe side effects while on HU (severe side effects include significant myelosuppression; skin cancer; or cytotoxicity evidenced by gastrointestinal symptoms, dermatological reactions, hepatic enzyme elevations, pulmonary fibrosis or neurological disturbances), or refusal of hydroxyurea therapy by the informed patient
  • Able to adhere to the study visit schedule and other protocol requirements
  • Females must be surgically sterile (post hysterectomy or bilateral oophorectomy) or naturally for at least 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months)
  • Male subjects must agree to use a latex condom during any sexual contact with females of child bearing potential (FCBP) during study drug treatment, during dose interruptions, and for at least 28 days following discontinuation of study drug even if they have undergone a successful vasectomy. Counseling about the requirement for latex condom use during sexual contact with FCBP and the potential risks of fetal exposure must be conducted at a minimum of every 28 days.
  • Male subjects must agree to abstain from donating semen or sperm while taking study drug and for 28 days after stopping study drug.
  • Both males and females must agree to abstain from donating blood while taking study drug and for 28 days after stopping study drug.
  • Both males and females must agree that they will not share study drug and will be counseled about the potential risks of fetal exposure.

Exclusion criteria

Exclusion Criteria:

  • Known positive status for human immune virus (), ; or acute/chronic, active
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form
  • Females of , pregnant or lactating females
  • Any condition, including the presence of laboratory abnormalities, which place the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Subjects unlikely to comply with , medication dosing, or study visit requirements
  • Subjects with severe or life threatening, active, unresolved infections
  • Any of the following laboratory abnormalities derived from the Screening Visit:

    • count or white blood cell count (WBC) less than the lower limit of normal (LLN)
    • Total less than or equal to 6.0 g/dL
    • Hemoglobin A (HbA) from transfusion greater than 20% at baseline
    • Creatinine greater than (ULN)
    • / Serum Glutamic Pyruvic Transaminase (ALT/SGPT) greater than 3 x ULN
    • Total greater than 10 mg/dL
  • Subjects on a chronic transfusion program
  • History of non-catheter related Deep Vein Thrombosis (DVT) or stroke
  • Chronic symptomatic constipation
  • History of cancer (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for at least three years.
  • Use of agents that can induce fetal hemoglobin within 90 days (three months) of Day 1 (i.e. HU, butyrates, decitabine, 5-azacytidine, or erythropoietin)
  • Use of experimental drug or treatment within 30 days of the first dose of study drug
  • History of allergic reaction to thalidomide or lenalidomide
  • Prior desquamating (blistering) rash while taking thalidomide or lenalidomide
  • Greater than or equal to a Grade 2 neuropathy
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Cohort 1: 0.5 mg pomalidomide

    0.5 mg pomalidomide orally daily for 84 days

    Drug: pomalidomide

  • Experimental
    Cohort 2: 1.0 mg pomalidomide

    1.0 mg pomalidomide orally daily for 84 days

    Drug: pomalidomide

  • Experimental
    Cohort 3: 2.0 mg pomalidomide

    2.0 mg pomalidomide orally daily for 84 days

    Drug: pomalidomide

  • Experimental
    Cohort 4: 3.0 mg pomalidomide

    3.0 mg pomalidomide orally daily for 84 days

    Drug: pomalidomide

  • Experimental
    Cohort 5: 4.0 mg pomalidomide

    4.0 mg pomalidomide orally daily for 84 days

    Drug: pomalidomide

Interventions

  • Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

    Also known as: CC-4047

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    Maximum Tolerated Dose

    Time frame: Up to 84 days

Secondary outcomes

  1. Adverse Events

    Type, frequency, and severity of adverse events, and relationship of adverse events to pomalidomide

    Time frame: Up to 169 days

  2. Absolute fetal hemoglobin change

    Percent of subjects with an absolute increase of 5% in percent fetal hemoglobin levels during study treatment

    Time frame: UP to 169 days

  3. % total hemoglobin

    Percent change in total hemoglobin from baseline to highest level

    Time frame: Up to 169 days

  4. Rate of total hemoglobin change

    Rate of change of total hemoglobin from baseline to highest level

    Time frame: Up to 169 days

  5. Inflammation markers and cytokines

    Change in serum inflammation markers and cytokines from baseline, during and at end of study treatment

    Time frame: Up to 169 days

07

Study locations

1 site
  • Karmanos Cancer Institute
    Detroit, Michigan 48201-2097, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2007 to primary completion in Oct 2012, 62 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 62 months is above that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2012
First posted
Jan 31, 2012
StartActual
Aug 1, 2007
Primary completionActual
Oct 1, 2012
CompletionActual
Dec 1, 2013
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01522547
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 31, 2012
Start date
Aug 1, 2007
Primary completion
Oct 1, 2012
Completion
Dec 1, 2013
Last update
Nov 8, 2019

Study contacts

Robert Knight, MD
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion